Micronized tanaproget and compositions containing same

a technology of micronized tanaproget and composition, which is applied in the direction of capsule delivery, drug composition, sexual disorder, etc., can solve the problem of increasing the risk of uterine cancer

Inactive Publication Date: 2006-11-02
WYETH LLC
View PDF6 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

ER agonists are used to treat the symptoms of menopause, but have been associated with a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Micronized Tanaproget

[0097] Tanaproget prepared according to US Patent Application Publication No. 2005 / 0272702, published Dec. 8, 2005 was milled using a U-10 Comil mill and thereby micronized using a MC50 Jetpharma Micronizer with an EZFH-1.4 Feeder. Particle size was tested periodically for a particle size of less than about 15 μm, and desirably less than about 10 μm, being distributed throughout 50% of the sample. The micronized tanaproget was packed in triple poly-bagged fiber drums. A desiccant was inserted between the outermost bags and the atmosphere in the bags replaced with nitrogen gas.

example 2

Directly Compressible Tablet Compositions Prepared By Employing Micronized Tanaproget

[0098] The tablet compositions for this example were manufactured using the following protocol and using the components of Table 4.

TABLE 4IngredientsFunctionMicronized TanaprogetActiveMicrocrystalline CelluloseFiller, Granulation(MCC), NF, (Avicel PH101)Aid, DisintegrantAnhydrous LactoseFillerCroscarmellose SodiumDisintegrantNF (Ac-Di-Sol)Magnesium StearateLubricant(Vegetable Source), NFCapsule ShellInactive

[0099] Anhydrous lactose and MCC were passed through a mesh screen and transferred to a 1 cu. ft. PK blender. The blended anhydrous lactose and MCC were passed through a mesh screen into a suitable poly bag. Micronized tanaproget was transferred to a suitable plastic bag. The tanaproget was pre-blended with a portion of the anhydrous lactose / MCC mixture. The pre-blend containing tanaproget / anhydrous lactose / MCC was transferred to the blender containing the remaining portion of anhydrous lactos...

example 3

Capsule Compositions Prepared By Employing Micronized Tanaproget

[0106] The capsule compositions for this example are manufactured using the following protocol and using the components set forth in Table 7.

TABLE 7IngredientsFunctionMicronized TanaprogetActiveMicrocrystalline Cellulose (MCC), NF,Filler, Granulation Aid,(Avicel PH101)DisintegrantCroscarmellose Sodium NF (Ac-Di-Sol)DisintegrantMagnesium Stearate, (Vegetable Source), NFFillerPovidone, K-17, USPBinderSodium Lauryl Sulfate (SLS), NFSurface active agentCapsule ShellInactive

[0107] Micronized tanaproget was added to a first plastic bag. A first portion of MCC was combined with the tanaproget and mixed. A second portion of MCC was combined with the blend of tanaproget and MCC and mixed. The blend containing both portions of MCC and tanaproget was passed through a #20 hand screen into a larger bag. The first plastic bag was rinsed with third and fourth portions of MCC, the rinsed products passed through the #20 hand screen i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Lengthaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefore Additional uses include stimulation of food intake.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit under 35 USC 119(e) of prior U.S. Provisional Patent Application No. 60 / 675,55 1, filed Apr. 28, 2005.BACKGROUND OF THE INVENTION [0002] Intracellular receptors (IR) form a class of structurally related gene regulators known as “ligand dependent transcription factors”. The steroid receptor family is a subset of the IR family, including the progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). [0003] The natural hormone, or ligand, for the PR is the steroid progesterone, but synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have been made which also serve as ligands. Once a ligand is present in the fluid surrounding a cell, it passes through the cell membrane via passive diffusion, and binds to the IR to create a receptor / ligand complex. This complex binds to specific gene promoters presen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/48A61K9/64
CPCA61K9/14A61K9/2018A61K9/2054A61K9/4808A61K31/536A61K9/141A61K9/4866A61P15/00A61P15/18A61P35/00A61P43/00A61P5/00A61P5/34
Inventor NAGI, ARWINDER S.CHATLAPALLI, RAMARAOHASAN, SHAMIMCARSON, ROLLAND W.GHORAB, MOHAMED
Owner WYETH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap